Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 597,268
  • Shares Outstanding, K 63,003
  • Annual Sales, $ 26,680 K
  • Annual Income, $ -211,843 K
  • 60-Month Beta 0.94
  • Price/Sales 17.40
  • Price/Cash Flow N/A
  • Price/Book 2.40
Trade ZYME with:

Options Overview Details

View History
  • Implied Volatility 79.29% ( +2.98%)
  • Historical Volatility 91.63%
  • IV Percentile 13%
  • IV Rank 25.78%
  • IV High 162.07% on 07/22/22
  • IV Low 50.55% on 10/10/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 145
  • Volume Avg (30-Day) 1,173
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 13,487
  • Open Int (30-Day) 10,577

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 4.62
  • Number of Estimates 3
  • High Estimate 5.03
  • Low Estimate 3.88
  • Prior Year -0.95
  • Growth Rate Est. (year over year) +586.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.31 +29.69%
on 01/10/23
10.80 -12.22%
on 01/19/23
+1.94 (+25.73%)
since 01/03/23
3-Month
5.76 +64.58%
on 12/13/22
10.80 -12.22%
on 01/19/23
+2.12 (+28.80%)
since 11/03/22
52-Week
4.11 +130.66%
on 09/07/22
10.80 -12.22%
on 01/19/23
+1.99 (+26.57%)
since 02/03/22

Most Recent Stories

More News
Strength Seen in CRISPR Therapeutics AG (CRSP): Can Its 7.2% Jump Turn into More Strength?

CRISPR Therapeutics AG (CRSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near...

CRSP : 55.27 (-1.51%)
ZYME : 9.48 (+2.49%)
Zymeworks Inc. (ZYME) Stock Sinks As Market Gains: What You Should Know

Zymeworks Inc. (ZYME) closed at $9.45 in the latest trading session, marking a -0.94% move from the prior day.

ZYME : 9.48 (+2.49%)
Zymeworks Inc. (ZYME) Dips More Than Broader Markets: What You Should Know

Zymeworks Inc. (ZYME) closed the most recent trading day at $9.78, moving -0.41% from the previous trading session.

ZYME : 9.48 (+2.49%)
Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor...

ZYME : 9.48 (+2.49%)
Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival

Jazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months.

JAZZ : 155.64 (-0.49%)
BGNE : 256.90 (+0.73%)
ZYME : 9.48 (+2.49%)
ALLO : 7.78 (-5.24%)
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease...

JAZZ : 155.64 (-0.49%)
ZYME : 9.48 (+2.49%)
Pre-Market Brief: Stocks Mostly Lower As Recession Worries Outweigh Cooler Inflation Data

March S&P 500 futures (ESH23) are trending down -0.41% this morning after three major U.S. benchmark indices ended the regular session lower as weak economic data and hawkish comments from Federal Reserve...

ESH23 : 4,147.75s (-1.04%)
CVAC : 11.06 (-5.31%)
AA : 52.74 (-1.71%)
NTLA : 43.23 (-3.07%)
DFS : 119.00 (+0.89%)
ZYME : 9.48 (+2.49%)
VNO : 24.85 (-5.62%)
How Much Upside is Left in Zymeworks Inc. (ZYME)? Wall Street Analysts Think 65.75%

The mean of analysts' price targets for Zymeworks Inc. (ZYME) points to a 65.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

ZYME : 9.48 (+2.49%)
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced updated key strategic priorities and provided updated financial...

ZYME : 9.48 (+2.49%)
Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why

Zymeworks (ZYME) recently entered a collaboration with Jazz Pharmaceuticals (JAZZ) for its lead pipeline candidate. This has been a significant catalyst for the stock.

SNY : 46.02 (-2.58%)
JAZZ : 155.64 (-0.49%)
KMDA : 4.69 (-1.47%)
ZYME : 9.48 (+2.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 10.63
2nd Resistance Point 10.28
1st Resistance Point 9.88
Last Price 9.48
1st Support Level 9.13
2nd Support Level 8.78
3rd Support Level 8.38

See More

52-Week High 10.80
Last Price 9.48
Fibonacci 61.8% 8.24
Fibonacci 50% 7.45
Fibonacci 38.2% 6.67
52-Week Low 4.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar